VERVE-102 not checked

Eli Lilly · LY4636581

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
Main trialPhase 2
“The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.”In the company’s words, NCT07839936 on ClinicalTrials.gov
Other names
LY4636581

Other drugs for Atherosclerosis

All 29 drugs for Atherosclerosis

Coming up1

Changes1

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Aug 2028 A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
Phase 1Recruiting Oct 2026 A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow VERVE-102

Following is part of Solo: you see every change to VERVE-102 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in